Business Description
![Outlook Therapeutics Inc Outlook Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000B22H.png?14)
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US68235M1053
Description
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.06 | |||||
Equity-to-Asset | -2.27 | |||||
Debt-to-Equity | -0.33 | |||||
Debt-to-EBITDA | -0.7 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.8 | |||||
3-Year EPS without NRI Growth Rate | 29 | |||||
3-Year FCF Growth Rate | 26.8 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.87 | |||||
9-Day RSI | 53.17 | |||||
14-Day RSI | 49.63 | |||||
6-1 Month Momentum % | 1.38 | |||||
12-1 Month Momentum % | -78.51 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.07 | |||||
Quick Ratio | 1.07 | |||||
Cash Ratio | 0.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27 | |||||
Shareholder Yield % | -43.71 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -376.23 | |||||
ROIC % | -152.34 | |||||
ROC (Joel Greenblatt) % | -16358.24 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -2.72 | |||||
EV-to-EBITDA | -2.72 | |||||
EV-to-Forward-Revenue | 30.87 | |||||
EV-to-FCF | -3.04 | |||||
Earnings Yield (Greenblatt) % | -36.76 | |||||
FCF Yield % | -33.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OTLK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -11.41 | ||
Beta | 0.03 | ||
Volatility % | 209.46 | ||
14-Day RSI | 49.63 | ||
14-Day ATR ($) | 0.490134 | ||
20-Day SMA ($) | 7.44575 | ||
12-1 Month Momentum % | -78.51 | ||
52-Week Range ($) | 4.004 - 36.998 | ||
Shares Outstanding (Mil) | 23.41 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Outlook Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(OTLK)'s stock price today?
The current price of OTLK is $7.52. The 52 week high of OTLK is $37.00 and 52 week low is $4.00.
When is next earnings date of Outlook Therapeutics Inc(OTLK)?
The next earnings date of Outlook Therapeutics Inc(OTLK) is 2024-08-14 Est..
Does Outlook Therapeutics Inc(OTLK) pay dividends? If so, how much?
Outlook Therapeutics Inc(OTLK) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |